Which BMY drug shows strongest revenue growth in 2024?

The drug that shows the strongest revenue growth for Bristol-Myers Squibb (BMY) in 2024 is Opdivo (nivolumab), with a revenue of $9.3 billion attributed to this segment.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Other Legacy Products|9.25E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Other Legacy Products|6.75E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Other Legacy Products|4.5E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Other Legacy Products|2.28E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Orencia|7.98E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Abraxane|2.17E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Opdualag|2.06E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Breyanzi|1.07E8|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Opdivo|2.078E9|169|
|BMY|BMY.N|Bristol-Myers Squibb|20240101-2024|Pomalyst/Imnovid|8.65E8|169|